ArticleJournal of managed care & specialty pharmacy2022

Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.

Murali Sundaram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.